PBE:NYE-Invesco Dynamic Biotechnology & Genome ETF (USD)

ETF | Health |

Last Closing

USD 63.296

Change

+1.21 (+1.94)%

Market Cap

N/A

Volume

0.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-02 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.96 (+0.67%)

USD 37.98B
FHLC Fidelity® MSCI Health Care In..

+0.53 (+0.79%)

USD 2.70B
FXH First Trust Health Care AlphaD..

+0.61 (+0.59%)

USD 1.01B
XHE SPDR® S&P Health Care Equipme..

+1.24 (+1.52%)

USD 0.18B
IDNA iShares Genomics Immunology an..

+0.42 (+2.08%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.78 (+2.89%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+0.46 (+0.47%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.32 (+1.18%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+1.34 (+2.36%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.72 (+4.36%)

USD 0.01B

ETFs Containing PBE

WBIR 0.00 % 1.25 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.86% 33% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.86% 33% F 29% F
Trailing 12 Months  
Capital Gain 0.03% 57% F 43% F
Dividend Return 0.01% 6% D- N/A F
Total Return 0.04% 38% F 33% F
Trailing 5 Years  
Capital Gain 40.13% 43% F 42% F
Dividend Return 0.10% 5% F N/A F
Total Return 40.23% 43% F 32% F
Average Annual (5 Year Horizon)  
Capital Gain 3.34% 48% F 47% F
Dividend Return 3.36% 48% F 38% F
Total Return 0.02% 11% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 17.96% 48% F 58% F
Risk Adjusted Return 18.68% 52% F 35% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.